Not just detection — function
Sequencing and PCR tell you what's present. DefenSight tells you what it's doing.
Syndromic PCR panels and genomic/proteomic assays are built to identify a known target — fast, specific, and essential for triage. But they answer presence, not consequence: they can't tell you whether an organism is viable or replicating, how a host cell is actually responding, or what's happening when the agent doesn't match a known signature. Imaging is the functional layer that sits alongside sequencing and PCR, not a replacement for either:
- Vs. syndromic PCR panels — phenotypic, host-response imaging remains informative even for novel, engineered, or unlisted agents, where no genetic target exists to probe for.
- Vs. sequencing/proteomics — those methods give you a population-level genotype or protein profile at a single time point. Imaging gives you a per-cell phenotype, tracked over time — the same quantitative rigour, applied to what the cell is actually doing rather than what it's carrying.
- For organoid, microtissue, and cell-line work — quantify phenotypic change, per cell, across infection, drug treatment, or both — not just whether a model responds, but how uniformly, how strongly, and on what timescale.
This is a dual-use capability: the same pipeline that supports CBRN triage supports antimicrobial and vaccine development screening. If your work spans detection and consequence assessment — or genotype and phenotype — this is the layer that connects them.
Built for your context
- Biosecurity & public health agencies — rapid, defensible triage of unknown or suspect samples, with outputs suitable for operational decision-making.
- Biopharma & antimicrobial/vaccine developers — quantitative, reproducible screening data for programs targeting parasites, viruses, and invasive bacteria.
- Defence & CBRN teams — a validated biological data layer that fits within existing mission and containment workflows.
Why DefenSight
DefenSight's analysis pipelines are built and reviewed by imaging scientists, not adapted from generic computer-vision tools. Our team brings direct, hands-on experience in quantitative confocal, super-resolution, high-content, and single-molecule imaging and analysis, using industry-standard platforms including Imaris, Fiji/ImageJ, and Zen. That background is why the QC gates and per-cell metrics we build hold up to expert scrutiny — they're designed by people who have run and validated these assays themselves.
Every engagement starts with a scoped conversation about your data, your hardware, and your decision requirements.
Get in touch to discuss a pilot.